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Small cell lung cancer (SCLC) is characterised by early and widespread metastasis. However, SCLC cells have so far been found to
produce low levels of known pro-angiogenic factors. We speculated that SCLC cells might produce alternative pro-angiogenic
factors. Here, we report that a panel of SCLC cell lines constitutively secrete granulocyte chemotactic protein-2 (GCP-2)/CXCL6, a
CXC ELRþ chemokine. In contrast, none of the three tested NSCLC cell lines secreted GCP-2. Production of GCP-2 in vivo was
also confirmed in seven out of nine specimens with SCLC. We demonstrate that expression of GCP-2 is mediated by NF-kBa s
ALLN, an NF-kB pathway inhibitor, almost completely abolished GCP-2 production in SCLC cell lines. We also demonstrate that
GCP-2 can be significantly upregulated by IL-1b and hypoxia in SCLC cell lines. This result suggests a role for GCP-2 in promoting
tumour progression in vivo under unfavourable conditions such as oxygen deprivation. As SCLC cells express both GCP-2 and its
receptors CXCR1 and CXCR2, their biological significance in SCLC progression was further studied. We demonstrate that GCP-2 is
an autocrine growth factor. Cell proliferation was significantly inhibited by anti-GCP-2 neutralising antibody in two high-GCP-2-
producing cell lines. In addition, expression of the proliferation marker PCNA was upregulated by exogenous GCP-2 in two low-
GCP-2-producing cell lines. Taken together, these results suggest an important role for GCP-2 as an autocrine mitogen in the growth
and metastasis of SCLC.
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Lung cancer is the leading cause of cancer-related deaths
worldwide. Small cell lung cancer (SCLC), which has a neuro-
endocrine phenotype, is characterised by early and widespread
metastasis. Despite initial chemosensitivity, resistant relapse is
common, and the poor prognosis has not improved in the past 20
years. The establishment of distant metastases, a process that is
pathognomic of cancer, depends on angiogenesis. Limited data are
available on the contribution of different angiogenic factors to
SCLC metastasis.
There is increasing evidence that chemotactic cytokines
(chemokines) and their receptors play key roles in cancer
progression and metastasis (Balkwill, 2004; Zlotnik, 2004). Many
angiogenic factors such as vascular endothelial growth factor
(VEGF), basic fibroblast growth factor (bFGF), platelet-derived
endothelial cell growth factor (PD-ECGF) and CXC chemokines are
associated with tumour progression and metastasis of lung cancer
(Cox et al, 2000). Among CXC chemokines, those with a conserved
Glu-Leu-Arg (ELRþ) N-terminal motif are pro-angiogenic,
whereas ELR  chemokines inhibit angiogenesis (Strieter et al,
1995). The ELRþ CXC chemokines include interleukin-8 (IL-8),
growth-related oncogenes-a,- b, and -g, granulocyte chemotactic
protein 2 (GCP-2) and epithelial neutrophil-activating protein-78
(ENA-78). The effects of ELRþ CXC chemokines are mediated
through binding to CXCR1 and CXCR2 receptors. All the ELRþ
CXC chemokines utilise the CXCR2 receptor, but only IL-8 and
GCP-2 recognise the CXCR1 receptor, which we found to be the
predominant receptor in lung cancer cells (Zhu et al, 2004).
Overexpression of IL-8 has been detected in non-small cell lung
cancer (NSCLC), where its expression correlates with tumorigenic
and metastatic potential (Yuan et al, 2000; Chen et al, 2003). We
have previously studied the expression of IL-8 and its receptors in
a panel of NSCLC and SCLC cell lines. We found that whereas
NSCLC produced high levels of IL-8, SCLC produced low levels of
IL-8. However, SCLC expressed higher levels of the IL-8 receptors,
CXCR1 and CXCR2 than NSCLC (Zhu et al, 2004). The only other
known ligand for CXCR1 receptor is GCP-2. This led us to examine
whether SCLC produces GCP-2.
Granulocyte chemotactic protein-2 was cloned as a neutrophil
chemoattractant (Proost et al, 1993). Like other CXC ELRþ
chemokines, GCP-2 was demonstrated to promote tumour growth
through its angiogenic effects in animal models (Strieter et al,
1995; Van Coillie et al, 2001). Recently, Gijsbers et al (2005)
reported that endothelial cells within gastrointestinal tumours
produced GCP-2 that was mitogenic to the endothelial cells and
motogenic to the endothelial cells and neutrophils. These results
confirmed that GCP-2 could play an important role in human
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stumour angiogenesis. Here, we show that GCP-2 is constitutively
secreted in a panel of SCLC cell lines and in clinical SCLC
specimens but not in NSCLC cell lines. We have investigated the
regulation of GCP-2 production and its biological functions in
SCLC.
MATERIALS AND METHODS
Lung cancer cell lines and reagents
The SCLC cell lines used were GLC-19, H69, H345, H711 and
Lu165. The NSCLC cell lines used were A549, H460 and MOR/P. All
cell lines were cultured in RPMI 1640 (BioWhittaker, Verviers,
Belgium) and 10% heat-inactivated FBS (QB perbio, Tattenhall,
Cheshire, UK) in humidified 5% CO2, 95% air at 371C. For hypoxic
experiments, the cells were incubated in a humidified Heto
multigas incubator in 0.5% O2,5 %C O 2 and 95% N2. ALLN
(Calpain Inhibitor; MG101) was purchased from Calbiochem
(Nottingham, UK). Mouse anti-human GCP-2, CXCR1 and CXCR2,
and rGCP-2 were purchased from R&D systems (Abingdon, UK).
The rabbit anti-human NF-kB (p65) antibody or rabbit anti-
human phosphorylated NF-kB (pp65) antibody were purchased
from Cell Signaling Technology (Beverly, MA, USA).
Reverse transcription-polymerase chain reaction
(RT–PCR)
Total RNA was isolated by using the RNeasy mini kit (Qiagen,
West Sussex, UK) following the manufacturer’s protocol. The
expression of mRNA for GCP-2 and GAPDH was determined by
RT–PCR as described previously (Zhu et al, 2003). The primers for
GCP-2 are as follows: sense, 50-CGC TGG TCC TGT CTC TGC T-30;
antisense, 50-GTT TTT CTT GTT TCC ACT GTC C-30. The primers
for GAPDH are as follows: sense, 50-CCA CCC ATG GCA AAT TCC
ATG GCA-30; antisense, 50-TCT AGA CGG CAG GTC AGG TCC
ACC-30. Amplification was carried out in a Biometra thermal cycler
after an initial denaturation at 941C for 3min. This was followed by
35 cycles of PCR using the following temperature and time profile:
denaturation at 941C for 40s, primer annealing at 581C for 40s,
primer extension at 721C for 1min, and a final extension of 721C
for 6min. The PCR products (235bp for GCP-2 and 593bp for
GAPDH) were visualized by electrophoresis on a 1.5% agarose gel
in 0.5 TBE buffer (44.5mM Tris borate, 1mM EDTA, pH 8.3) after
staining with 0.5mgml
 1 ethidium bromide.
Enzyme-linked immunosorbent assay (ELISA)
Granulocyte chemotactic protein-2 concentrations in the culture
media were determined by ELISA (R&D systems, Abingdon, UK)
as previously described for IL-8 (Zhu et al, 2003; Zhu et al, 2004).
The concentration of GCP-2 was determined by measuring the
optical density (OD) at 450nm in a Dynatech MR5000 microplate
reader.
Flow cytometry analysis of cell surface expression of
CXCR1 and CXCR2
The cells were washed twice with phosphate-buffered saline (PBS)
and then suspended in 100ml of FACS buffer (2% bovine serum
albumin, 2% normal rabbit serum in PBS), and then 2mg of mouse
anti-human monoclonal anti-CXCR1 or anti-CXCR2 antibody or
IgG control antibody (R&D systems) were added and incubated for
40min on ice. After washing twice with PBS, the cells were
suspended in 100ml of FACS buffer plus 1:20 diluted fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (Dako-
Cytomation, Ely, UK) and incubated for 30min on ice. The cells
were washed twice with PBS and fixed in 100ml of FACS buffer
containing 1% paraformaldehyde. The cells were analysed on a
FACSort flow cytometer (Becton Dickinson, San Jose, CA, USA).
Western blotting and immunofluorescences
For NF-kB p65 and pp65 detection, nuclear and cytoplasmic
extracts were prepared as follows: cells were first lysed in 10mM
Tris-HCl (pH 7.9), 60mM KCl, 1mM EDTA, 1mM DTT, 1mM
Pefabloc, 50mgml
 1 antipain, 100mgml
 1 chymostatin, 1mgml
 1
leupeptin, 1mgml
 1 pepstatin, 40mgml
 1 bestatin, 3mgml
 1 E-64
and 0.1% NP-40. The cytoplasmic fraction was removed and the
pellet resuspended in 20mM Tris-HCl (pH 8.0), 400mM NaCl,
1.5mM MgCl, 1.5mM EDTA, 1mM DTT, 25% glycerol, 1mM
Pefabloc, 50mgml
 1 antipain, 100mgml
 1 chymostatin, 1mgml
 1
leupeptin, 1mgml
 1, pepstatin, 40mgml
 1 bestatin and 3mgml
 1
E-64. The nuclear fraction was removed. For GCP-2 detection, cells
were lysed in Cellytict Mammalian cell lysis extraction buffer
(Sigma, Poole, Dorset, England). The protein concentration was
determined by the Bradford assay. A measure of 20mg of protein
was used per lane. The detailed procedure from gel eletrophoresis
to detection was described previously (Zhu et al, 2003). Expression
of NF-kB p65 was also detected by immunofluorescence as
described by Zhu et al (2003). Briefly, SCLC cells were fixed in
4% paraformaldehyde in PBS, permeabilized with 0.2% Triton X-
100. Each slide was incubated with blocking solution (1.5% goat
serum in PBS), then with diluted rabbit anti-human NF-kB (1:200
dilution) antibody, and finally with 1:160 diluted FITC-conjugated
goat anti-rabbit secondary antibody. The slides were then mounted
onto slides with Vectashield mounting medium (Vector Labora-
tories, Inc., Burlingam, CA, USA). Fluorescence was observed and
photographed using a Zeiss microscope.
MTT assay
Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, Dorset,
England). A total of 5 10
3 cells were seeded into 96-well flat-
bottomed plates in triplicate in 100ml RPMI containing 0.5% FCS.
After overnight culture, cells were treated with various concentra-
tions of monoclonal anti-GCP-2 antibody or control antibody
mouse IgG for 24 and 48h. A volume of 10ml of MTT (5mgml
 1)
was added to each well 4h before the end of experiments. MTT
solvent (100ml of 0.1N Hcl in anhydrous isopropanol) was added
and absorbance of the converted dye was measured at a
wavelength of 570nm. The background was also measured at
690nm.
Statistical analysis
All results are expressed as mean7s.e.m. The unpaired Student’s
t-test was used to evaluate the significance of differences between
groups, accepting Po0.05 as the level of significance.
RESULTS
Release of granulocyte chemotactic protein-2 from small
cell lung cancer but not from non-small cell lung cancer
Granulocyte chemotactic protein-2 protein was measured in
conditioned serum-free medium of a panel of SCLC and NSCLC
cell lines by ELISA. Constitutive release of GCP-2 was found in all
five SCLC cell lines but in none of the three NSCLC cell lines
(Figure 1A). After 24h, the concentration of GCP-2 in the SCLC-
conditioned medium was 1080772pgml
 1/2 10
6 cells in H711,
907740pgml
 1/2 10
6 cells in H345, 377724pgml
 1/2 10
6
cells in H69, 346731pgml
 1/2 10
6 cells in GLC-19 and
216730pgml
 1/2 10
6 cells in Lu165. GCP-2 was also detected
in cell lysates by Western blotting (Figure 1A) although low levels
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swere found in cell lysates by ELISA (data not shown), suggesting
that GCP-2 is released from cells soon after synthesis. The
production of GCP-2 in vivo was confirmed by immunohisto-
chemistry on biopsy samples from nine SCLC patients (Figure 1B).
GCP-2 was positive in seven out of nine patients (78%).
Constitutive expression of granulocyte chemotactic
protein-2 is abolished by targeting NF-jB
The 50 flanking region of GCP-2 has been cloned and binding sites
for three major transcription factors identified there: nuclear
factor (NF)-kB, NF-IL-6 and activating protein (AP)-2 (Rovai et al,
1997). We investigated the role of NF-kB in regulating GCP-2
activity in SCLC cell lines. Using antibodies specific for total NF-
kB p65 and phosphorylated p65, we studied the cellular distribu-
tion of phosphorylated and unphosphorylated p65 (Figure 2A).
p65 was found in both the nuclear and cytoplasmic cell fractions
but phosphorylated p65 was located only in the nucleus. To test
whether NF-kB regulated GCP-2 expression, the NF-kB signal
pathway was targeted in two high-GCP-2-producing cell lines:
H711 and H345. ALLN, which prevents IkB degradation and hence
inhibits nuclear translocation of NF-kB (Figure 2C), significantly
reduced GCP-2 release in a dose-dependent fashion in both H711
and H345 cells (Figure 2B). GCP-2 was reduced to 355744pgml
 1
(67% reduction, Po0.01) at a final concentration of 10mM of ALLN
and further reduced to 8374pgml
 1 (92% reduction, Po0.001) at
50mM of ALLN from 1078726pgml
 1 at control in H711. GCP-2
was reduced to 7178pgml
 1 (91% reduction, Po0.001) at 10mM
of ALLN and further reduced to 4173pgml
 1 (95% reduction,
Po0.001) at 50mM of ALLN from 815725pgml
 1 at control in
H345. Granulocyte chemotactic protein-2 was also reduced to less
than 1171pgml
 1 at 10mM of ALLN from 277734pgml
 1 in H69
(96% reduction, Po0.001).
Regulation of granulocyte chemotactic protein-2 secretion
by IL-1b
IL-1b has been shown to be the predominant inducer of GCP-2 in
non-tumour cells such as mesenchymal cells (Wuyts et al, 2003)
and endometrial stromal cells (Mine et al, 2003). To assess whether
IL-1b induces GCP-2 in SCLC cell lines, the high-GCP-2-producing
H345 and H711 cells were treated by rIL-1b at a final concentration
of 0.1 or 1ngml
 1 for 24h (Figure 3A). A significant increase in
GCP-2 release was found at 0.1ngml
 1 in both H345 (84%
increase, Po0.01) and H711 (53% increase, Po0.01) cell lines. No
further increase of GCP-2 was found when IL-1b was increased to
1ngml
 1 (Figure 3A). As shown by RT–PCR, IL-1b upregulated
GCP-2 mRNA in both cell lines, indicating that the upregulation is
mediated by increased transcription of GCP-2 (Figure 3B).
Upregulation of GCP-2 by hypoxia
To test whether hypoxia upregulates GCP-2, H711 cells were
cultured under normoxia and hypoxia (0.5% O2) for 24, 48 and
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Figure 1 Expression and release of GCP-2 from SCLC cells but not
from NSCLC cells. (A) GCP-2 protein was measured by ELISA in 24h-
conditioned serum-free medium of a panel of SCLC and NSCLC cell lines.
Constitutive release of GCP-2 was found in all the five SCLC cell lines but
in none of the three NSCLC cell lines. GCP-2 was also detected in cell
lysates from SCLC but not from NSCLC cell lines by Western Blotting.
Each bar is the mean7s.e.m. of three determinations from three
indepedent experiments. (B) Production of GCP-2 in vivo was confirmed
by immunohistochemistry on biopsy samples in seven out of nine patients
(78%).
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Figure 2 Constitutive expression of GCP-2 in SCLC cells is mediated by
NF-kB. (A) Expression of NF-kB p65 was detected by Western blotting in
both cytoplasmic (C) and nuclear (N) fractions in SCLC cell lines. In
contrast, phosphorylated p65 (pp65) was only detected in nuclear fractions
in those cells. (B) ALLN significantly reduced GCP-2 release, measured by
ELISA, in a dose-dependent fashion in H711, H345 and H69 cells. GCP-2
was reduced at least 80% when cells were treated at a final concentration
of 10 and 50mM of ALLN in all SCLC cell lines tested. Each bar is the
mean7s.e.m. of three determinations from two independent experiments.
(C) Nuclear p65, detected by immunofluorescence, was reduced following
treatment with ALLN at a final concentration of 10mM in H345 cells.
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s72h (Figure 4A). GCP-2 was increased from between 1000780
(24h) and 940720 (72h)pgml
 1 under normoxia to
1460740pgml
 1 under hypoxia (46% increase, Po0.01) at 24h,
to 23207240pgml
 1 (152% increase, Po0.01) ) at 48h and to
2380740pgml
 1 (153% increase, Po0.001) at 72h. We further
studied the effects of 48h hypoxia on GCP-2 production in a panel
of SCLC cell lines. Granulocyte chemotactic protein-2 production
was significantly upregulated (range from 34% in H69 to 129%
increase in GLC19) in all tested SCLC cell lines (Figure 4B).
Granulocyte chemotactic protein-2 is an autocrine mitogen
for small cell lung cancer cells
Expression of the GCP-2 receptors CXCR1 and CXCR2 was studied
by FACS. We found that all the SCLC cell lines express functional
GCP-2 receptors (Figure 5). As SCLC cells express both GCP-2 and
its receptors, we speculated that it could act as an autocrine growth
factor for these cells. To test this, SCLC cells were treated with
neutralising anti-GCP-2 antibody for 48h. As measured by MTT
assay, cell proliferation was significantly inhibited by 26%
(Po0.01) in H711 and by 21% (Po0.05) in H345, but cell lines
GLC-19, H69 and Lu165 were not significantly affected (Figure 6A).
We also studied the effects of exogenous GCP-2 on cell
proliferation by examining the expression of the proliferation
marker, proliferating cell nuclear antigen (PCNA) by flow
cytometry with mouse anti-human PCNA monoclonal antibody
and control mouse IgG2a antibody. The results are expressed as
the mean fluorescent intensity. Recombinant GCP-2 (0.1–
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Figure 3 Upregulation of GCP-2 secretion by IL-1b.( A) IL-1b
upregulated GCP-2 mRNA detected by RT–PCR in both H711 and
H345 cell lines. (B) GCP-2 release was upregulated at 0.1ngml
 1 in both
H345 (84% increase, Po0.01) and H711 (53% increase, Po0.01) cell lines,
and at 1ngml
 1 after H345 and H711 cells were treated by rIL-1b for 24h.
Each bar is the mean7s.e.m. of three determinations.
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Figure 4 Upregulation of GCP-2 by hypoxia. (A) H711 cells were
cultured under normoxia and hypoxia (0.5% O2) for 24, 48 and 72h.
Granulocyte chemotactic protein-2 measured by ELISA was significantly
increased by 46% (Po0.01) at 24h, 152% (Po0.01) at 48h and 153%
(Po0.001) at 72h. (B) The effects of 48h hypoxia on GCP-2 production
in a panel of SCLC cell lines. Granulocyte chemotactic protein-2 production
measured by ELISA was significantly upregulated (range from 34% in H69
to 129% increase in GLC19) in all tested SCLC cell lines. Each bar is the
mean7s.e.m. of three determinations from two independent experiments.
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Figure 5 Expression of CXCR1 and CXCR2 on SCLC cells. Expression
of the CXCR1 and CXCR2 was detected by FACS in a panel of SCLC cell
lines. All the SCLC cell lines express functional GCP-2 receptors.
Expression of CXCR1 (right histogram) were higher than CXCR2 (middle
histogram) in all SCLC cell lines.
GCP-2 in small cell lung cancer
YM Zhu et al
1939
British Journal of Cancer (2006) 94(12), 1936–1941 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s10ngml
 1) upregulated the expression of PCNA in a dose-
dependent fashion in two low-GCP-2-producing cell lines H69
and GLC19. Expression of PCNA increased five-fold in H69 and
three-fold in GLC-19 cells when the cells were treated with rGCP-2
at a final concentration of 10ngml
 1 (Figure 6B). In contrast,
expression of PCNA was no significantly increased after rGCP-2
treatment in the two high-GCP-2-producing cell lines, H711 and
H345, or in Lu165.
DISCUSSION
Granulocyte chemotactic protein-2 was originally isolated from
conditioned medium of osteosarcoma cells (Proost et al, 1993).
Subsequent studies have shown that GCP-2 was produced in
tumour cell lines such as MG-63, HeLa, and Bowes. It has been
shown to have mitogenic and angiogenic properties in different
models (Strieter et al, 1995; Van Coillie et al, 2001). Like other
ELRþ CXC chemokines, GCP-2 was chemotactic to endothelial
cells in vitro and promoted rat cornea neovascularization in vivo
(Strieter et al, 1995). Van Coillie et al (2001) showed that tumour-
derived GCP-2 increased angiogenesis through activation of
tumour-associated neutrophils and intratumoral expression of
gelatinase B. GCP-2 binds to both CXCR1 and CXCR2 with similar
high affinity. Both receptors are G protein-coupled seven-
transmembrane domain receptors, but different biological func-
tions may be mediated by the different receptors. CXCR1 is
believed to mediate the chemotactic activity, whereas CXCR2
mediates the angiogenic activity of CXC ELRþ chemokines such
as IL-8 (Heidemann et al, 2003; Ramjeesingh et al, 2003; Bates
et al, 2004).
Angiogenesis and metastasis are essential to tumour develop-
ment. Angiogenic factors have been extensively described in
NSCLC but not in SCLC. Expression of VEGF was detected in 43 of
54 (81%) patients with SCLC, but was not associated with survival
(Dowell et al, 2004) although increased expression of VEGF in
SCLC was associated with poorer prognosis in another indepedent
study (Fontanini et al, 2002). To date SCLC cells have been found
to produce lower levels than NSCLC of pro-angiogenic factors such
as VEGF and IL-8 (Yatsunami et al, 1997). This suggests that SCLC
might utilise different angiogenic factors than NSCLC. In this
study, we report that SCLC cells secrete GCP-2, whereas NSCLC
cells do not, as shown by ELISA of conditioned media in cell
culture, Western blotting of cell lysates and immunohisto-
chemistry of tumour specimens. This finding demonstrates that
SCLC cells secrete an additional pro-angiogenic factor to NSCLC.
We therefore further studied the regulation and function of GCP-2
in SCLC.
We investigated the role of NF-kB (p65), a crucial transcription
factor that mediates chemokine induction, in GCP-2 secretion by
exposing cells to ALLN, which stabilises IkB. ALLN almost
completely abolished GCP-2 secretion in H345 and H711 cells,
suggesting that NF-kB is a major regulator of GCP-2 expression in
SCLC. We further tested whether IL-1b upregulated GCP-2 in
SCLC cells. Both mRNA and protein of GCP-2 were significantly
increased in two SCLC cell line tested. This result suggests that
upregulation of GCP-2 by IL-1b is initiated at the transcriptional
level. IL-1b has been found to induce NF-kB activation in cancer
cells such as leukaemic cell line OCIM2 (Estrov et al, 1999).
Therefore, upregulation of GCP-2 by IL-1b may be mediated by
NF-kB induction.
Granulocyte chemotactic protein-2 is one of the CXC ELRþ
chemokines with pro-angiogenic properties. GCP-2 has previously
been shown to act as an angiogenic factor (Strieter et al, 1995).
Many angiogenic factors are induced when tumour cells are
exposed to unfavourable conditions such as hypoxia. We therefore
investigated the role of hypoxia on GCP-2 production in SCLC
cells. We found that GCP-2 was significantly increased in all SCLC
cell lines after 48h in 0.5% O2. Among them, GCP-2 production
was increased by over 120% in H711 and GLC19 cell lines. The
underlying mechanism of upregulation of GCP-2 by hypoxia in
SCLC has not yet been defined. We scrutinised the promoter
region of GCP-2 (Mine et al, 2003), and found a potential hypoxia-
inducable factor (HIF) DNA binding site (GCGTG) (Wenger and
Gassmann, 1997) present in the hypoxia-response element (HRE)
from  430 to  424 within the promoter of GCP-2. It has been well
documented that HIF is rapidly stabilised upon exposure to
hypoxia (Wenger, 2000). Therefore, HIF may mediate GCP-2
upregulation by hypoxia in SCLC cells. In addition to HIF, NF-kB
may play a role in the upregulation of GCP-2 by hypoxia. Hypoxia
can upregulate genes without an HRE in their promoters and such
hypoxia-induced gene induction was NF-kB-dependent (Karashi-
ma et al, 2003). The mechanism of GCP-2 upregulation by hypoxia
merits further study.
As SCLC cells expressed CXCR1 and CXCR2 on the cell
membrane and secrete GCP-2, we further investigated the
biological functions of GCP-2 in SCLC in this study. Expression
of PCNA, a marker of cell proliferation, was significantly increased
after SCLC cells were treated with rGCP-2 in at least two low GCP-
2-producing cell lines GLC19 and H69. Cell proliferation was
inhibited after the cells were treated with neutralising anti-GCP-2
antibody in two high-GCP-2-producing cell lines (H711 and H345),
A
B
H711 H345 GLC19 H69 Lu165
300
400
500
600
700
0
1
10
Anti-GCP-2 Ab (g ml–1)
*
**
*
*
M
T
T
0.125 0.25 0.5 1 2 4 8 16
0
50
100
150
200
250
300
350 H69
GLC19
H711
H345
Lu165
rGCP-2 (ng ml−1)
P
C
N
A
 
(
M
F
I
)
Figure 6 Granulocyte chemotactic protein-2 is an autocrine mitogen for
SCLC cells. (A) After SCLC cells were treated with neutralising anti-GCP-2
antibody for 48h, cell proliferation was significantly inhibited by 26%
(Po0.01) in H711 and by 21% (Po0.05) in H345, but not affected in H69,
GLC19 and Lu165. Each bar is the mean7s.e.m. of three determinations
from two independent experiments. (B) The expression of PCNA was
measured by flow cytometry following the treatment of exogenous GCP-2.
The results are expressed as the mean fluorescent intensity. rGCP-2 (0.1–
10ngml
 1) upregulated the expression of PCNA in dose-dependent
manner in two low-GCP-2-producing cell lines H69 and GLC19. In
contrast, expression of PCNA was not increased after rGCP-2 treatment in
high-GCP-2-producing cell lines H711 and H345, or in Lu165.
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Lu165. These results suggest that GCP-2 may act as an autocrine
growth factor in SCLC cells. Interleukin-8 (IL-8), which shares the
CXCR1 and CXCR2 receptors with GCP-2, was also found to be
mitogenic to SCLC (Zhu et al, 2004). The signal transduction
pathways mediating the mitogenic function of IL-8 are complex,
include extracellular signal-regulated kinase (ERK) of mitogen-
activated protein kinase (MAPK) pathway, NF-kB, and epidermal
growth factor receptor (EGFR) pathway by cross-talk (Zhu and
Woll, 2005). As the GCP-2 binds to the same receptors, we
speculate that the same pathways will be utilised.
In summary, we showed that SCLC cells constitutively secrete
GCP-2 chemokine but NSCLC cells do not. GCP-2 production can
be significantly upregulated by IL-1b and hypoxia. Granulocyte
chemotactic protein-2 production is mediated by NF-kB. In
addition to its angiogenic property previously shown in other
studies, we demonstrated that GCP-2 can act as an autocrine
growth factor to most SCLC cells. Thus, GCP-2 could be critical to
the tumour development in SCLC. These results suggest that
targeting GCP-2 may inhibit tumour growth in SCLC.
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